866640-75-7

Upstream product

• 866640-73-5 C-[2-(3-Bromophenyl)-5-methyloxazol-4-yl]methylamine 
• 51336-35-7 α-(4-formylphenoxy)isobutyric acid ethyl ester 
• 123-08-0 4-hydroxy-benzaldehyde 
• 600-00-0 ethyl 2-bromoisobutyrate 

Downstream Products

• 1415228-36-2 C₂₉H₂₇BrN₂O₅ 
• 1415228-31-7 C₃₁H₃₁BrN₂O₅ 

Relevant academic research and scientific papers

Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1)

We describe here the design, syntheses and structure-activity relationships (SAR) of novel zwitterionic compounds as non-thiazolidinedion (TZD) based peroxisome proliferator activated receptor (PPAR) α/γ dual agonists. We commenced the medicinal research

PHENOXYACETIC ACID DERIVATIVES AND DRUGS USING THE SAME

It is intended to provide a novel compound having an excellent agonism to PPARs α/γ and desirable properties as a drug. An agonist to peroxisome proliferator-activated receptors α/γ which is represented by the general formula (I) (wherein Q represents an optionally substituted benzene ring or pyridine ring; R1 and R2 represent each an optionally substituted phenyl group or a 5- to 6-membered aromatic heterocycle group; X, Y and Z independently represent each C, O, S or N; R3 to R9 represent each a hydrogen atom, a lower alkyl group, etc.; and n is an integer of from 0 to 3.

PHENOXYACETIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME

Novel compounds having excellent PPAR α/γ agonist effects and having desirable properties for medicaments are provided. Peroxisome proliferator-activated receptor α/γ agonists of the general formula (I): (wherein Q is an optionally-substituted benzene or